Inicio・Lista de Acciones・AbCellera Biologics Inc

AbCellera Biologics Inc

Cerrado

SectorSanidad

6.44 4.04

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

5.71

Máximo

6.55

Métricas clave
By Trading Economics
Ingresos	-34M -43M
Ventas	-37M 8.3M
BPA	-0.14
Margen de beneficios	-519.122
Empleados	562
EBITDA	-23M -41M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+82.94% upside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	178M 1.8B
Apertura anterior	2.4
Cierre anterior	6.44

Noticias sobre sentimiento de mercado

By Acuity

47%

53%

159 / 340 Clasificación en Healthcare

AbCellera Biologics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 ago 2026, 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

5 ago 2026, 23:02 UTC

Social Media

News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

3 ago 2026, 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

31 jul 2026, 19:33 UTC

Correlated Moves

Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

30 jul 2026, 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

29 jul 2026, 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

28 jul 2026, 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

27 jul 2026, 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

24 jul 2026, 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

22 jul 2026, 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

21 jul 2026, 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

20 jul 2026, 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Comparación entre iguales

Cambio de precio

AbCellera Biologics Inc previsión

Precio Objetivo

By TipRanks

82.94% repunte

Estimación a 12 Meses

Media 10.83 USD 82.94%

Máximo 13 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbCellera Biologics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para AbCellera Biologics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

159 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.